Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect of Darigabat in Healthy Adults
NCT05123079Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Nov 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of darigabat in epilepsy and panic disorder (3 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Peak Plasma Concentration, Area Under the Plasma Concentration-Time Curve and 1 more. Started Nov 2021; status: completed.
02
Drugs
darigabat
03
Conditions
epilepsypanic disorder
Beyond the preview
Go deeper on NCT05123079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123079.